Kymera Therapeutics (KYMR) Depreciation and Depletion (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Depreciation and Depletion data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Depreciation and Depletion changed 0.0% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 10.67% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, up 12.16% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $1.6 million, down from $2.9 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for KYMR reached as high as $2.9 million in Q4 2025 and fell as low as $700000.0 in Q1 2022.
• Historically, Depreciation and Depletion has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
• On a YoY basis, Depreciation and Depletion climbed as much as 114185.71% in 2022 and fell as far as 66.64% in 2022.
• Year by year, Depreciation and Depletion stood at $800000.0 in 2022, then gained by 12.5% to $900000.0 in 2023, then surged by 122.22% to $2.0 million in 2024, then soared by 45.0% to $2.9 million in 2025, then plunged by 44.83% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Depreciation and Depletion figures were $1.6 million in Q1 2026, $2.9 million in Q4 2025, and $2.1 million in Q3 2025.